Thyrocare Technologies Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹224Cr
- +19.8% YoY
- +14.3% QoQ
- Net profit
- ₹49Cr
- +122.7% YoY
- +75% QoQ
- Margin
- 34%
- +4 pp YoY
- +4 pp QoQ
Guidance rank: #16 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Specialty testing market opportunity estimated at INR 7,000 to 10,000 crores over 2-3 years, indicating growth potential in specialty and allied services. FY '26 reported a strong profit after tax (PAT) of INR163 crores, up 81% YoY, with EPS of INR2.99, up 64% YoY.
From Thyrocare Technologies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Specialty testing market opportunity estimated at INR 7,000 to 10,000 crores over 2-3 years, indicating growth potential in specialty and allied services.
- Q4 FY26 test volume growth surged to ~29%, driven by competitive pricing in biochemistry tests.
- Expected mid- to high-teens revenue growth for FY27, primarily volume-driven (~75%), with mix contributing ~25%.
- Franchise addition targeted at ~500 per quarter, maintaining steady expansion and increasing average revenue per franchisee due to expanded test menu.
- No price hikes planned; growth driven by volume and service mix improvements.
2 more points from Thyrocare Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY'26 capex payout was around INR20-35 crores, relatively low compared to operating cash flow.
- Total capitalization during FY'26 was around INR35 crores, including new labs and genomics investments.
- Maintenance capex is roughly around INR40 crores, with expansion capex expected in a similar range.
- New lab openings: 7 labs added in FY'26 (Bhagalpur, Mandi, Roorkee, Kashmir, Davanagere, Vijaywada, Gwalior).
- Focus on franchise addition as a primary growth driver, which is asset-light and limits heavy capex needs.
- Investments in genomic and specialty diagnostics with capex estimates around INR5-8 crores.
- Major investments for specialty diagnostics are on operational expenditure (field force of ~40 people).
2 more points from Thyrocare Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Thyrocare Technologies Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 224 | 187 | +19.8% | 196 | +14.3% |
| Operating profit (EBITDA) | 75 | 57 | +31.6% | 58 | +29.3% |
| Operating margin | 34% | 30% | +4 pp | 30% | +4 pp |
| Profit before tax | 64 | 47 | +36.2% | 35 | +82.9% |
| Net profit (PAT) | 49 | 22 | +122.7% | 28 | +75% |
| EPS (₹) | 2.96 | 1.36 | +117.6% | 1.82 | +62.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Thyrocare Technologies's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Sciences (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q4 FY26 results?
Specialty testing market opportunity estimated at INR 7,000 to 10,000 crores over 2-3 years, indicating growth potential in specialty and allied services. FY '26 reported a strong profit after tax (PAT) of INR163 crores, up 81% YoY, with EPS of INR2.99, up 64% YoY.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
FY'26 capex payout was around INR20-35 crores, relatively low compared to operating cash flow.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
